Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AIDS Dementia Complex Clear all
Completed Phase 1 Interventional

Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy

NCT00002209
View directory record Official record
Conditions
AIDS Dementia Complex, HIV Infections
Interventions
CPI-1189
Drug
Lead sponsor
Centaur Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Not applicable Interventional

A Study of Decreased Mental Function Associated With HIV

NCT00027040
View directory record Official record
Conditions
Cognitive Disorders, HIV Infections
Interventions
Selegiline hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
12
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients

NCT00013585
View directory record Official record
Conditions
Cognition Disorders, HIV Infections
Interventions
Selegiline hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Honolulu, Hawaii + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects

NCT03581305
View directory record Official record
Conditions
Depression, HIV Infections, HIV-Associated Cognitive Motor Complex
Interventions
18F-FDOPA, 11C-DASB
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Trial of CNS-targeted HAART (CIT2)

NCT00624195
View directory record Official record
Conditions
HIV Infections
Interventions
FDA Approved Antiretroviral Therapy (see list below)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
San Diego, California • San Francisco, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 4 Interventional Results available

Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)

NCT01600170
View directory record Official record
Conditions
HIV Dementia
Interventions
Atorvastatin (generic Lipitor), placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2 Interventional

Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex

NCT00000657
View directory record Official record
Conditions
AIDS Dementia Complex, HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
13
States / cities
San Francisco, California • Indianapolis, Indiana • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2Phase 3 Interventional

Maraviroc and NeuroAIDS Pathogenesis

NCT02159027
View directory record Official record
Conditions
AIDS Dementia Complex
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)

NCT00000867
View directory record Official record
Conditions
AIDS Dementia Complex, HIV Infections
Interventions
Memantine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex

NCT00002246
View directory record Official record
Conditions
AIDS Dementia Complex, HIV Infections
Interventions
Stavudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
3
States / cities
San Diego, California • West Hollywood, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS

NCT02678767
View directory record Official record
Conditions
AIDS Dementia Complex
Interventions
Ferumoxytol
Drug
Lead sponsor
Beau Nakamoto
Other
Eligibility
40 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 4 Interventional Results available

Modulation of Monocyte Activation by Atorvastatin in HIV Infection

NCT01263938
View directory record Official record
Conditions
HIV Dementia
Interventions
Atorvastatin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Not applicable Interventional

A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases

NCT00002044
View directory record Official record
Conditions
AIDS Dementia Complex, Neuromuscular Diseases, HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1

NCT00000738
View directory record Official record
Conditions
AIDS Dementia Complex, HIV Infections
Interventions
Nimodipine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
12
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 2:35 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)

NCT00459693
View directory record Official record
Conditions
HIV-Dementia, HIV-Associated Cognitive Motor Complex, AIDS Encephalopathy, AIDS Dementia Complex, AIDS-Related Dementia Complex, HIV Infections, Healthy
Interventions
[11C]PBR28
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2 Interventional

A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia

NCT00002154
View directory record Official record
Conditions
Cognitive Disorders, HIV Infections
Interventions
Thioctic acid, Selegiline hydrochloride
Drug
Lead sponsor
The Dana Foundation
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 3 Interventional

An Open Trial of Zidovudine (AZT) Treatment of the AIDS Dementia Complex in Patients With AIDS or Low CD4+ Lymphocyte Counts

NCT00000709
View directory record Official record
Conditions
AIDS Dementia Complex, HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
12
States / cities
Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

Effect of Galantamine on Inflammation and Cognition

NCT03384784
View directory record Official record
Conditions
HIV Associated Cognitive Motor Complex
Interventions
Galantamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia

NCT00002148
View directory record Official record
Conditions
Cognitive Disorders, HIV Infections
Interventions
OPC 14117
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 3 Interventional

A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex

NCT00002163
View directory record Official record
Conditions
AIDS Dementia Complex, HIV Infections
Interventions
Abacavir sulfate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 2:35 PM EDT
Not listed Phase 2 Interventional

Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia

NCT00002414
View directory record Official record
Conditions
HIV Infections
Interventions
CPI-1189
Drug
Lead sponsor
Centaur Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
San Diego, California • Chicago, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 2:35 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Intranasal Insulin for the Treatment of HAND

NCT03081117
View directory record Official record
Conditions
HIV Dementia, HIV-Associated Cognitive Motor Complex
Interventions
Insulin, intranasal, Placebo, intranasal
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 69 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders

NCT01665846
View directory record Official record
Conditions
HIV Dementia
Interventions
Ferumoxytol
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
19 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 22, 2026, 2:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mental Ability Challenge Study in Adults With and Without HIV

NCT03244488
View directory record Official record
Conditions
HIV-1-infection, Aging, Premature, Cognitive Impairment, Memory Impairment, HIV-Associated Cognitive Motor Complex
Interventions
Scopolamine Injectable Product, Mecamylamine Pill
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
35 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 22, 2026, 2:35 PM EDT